Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy

Atezolizumab in combination with cabozantinib is in clinical development for the treatment of advanced renal cell carcinoma (RCC) after prior treatment. RCC (also called kidney cancer) is a disease that affects the lining of tiny tubes within the kidney which filter waste from the blood, making urine. In many cases of RCC there are no obvious symptoms at first, and kidney cancer is found during tests for another reason. RCC is called advanced when the tumour has spread to other parts of the body. Some patients experience drug resistance to existing single drug therapies and require the use of more effective combination therapies.